share_log

Stifel Maintains Buy on DexCom, Lowers Price Target to $132

Stifel Maintains Buy on DexCom, Lowers Price Target to $132

斯提费尔保持对德康医疗的买入评级,将目标价格下调至132美元。
Benzinga ·  07/12 08:46

Stifel analyst Mathew Blackman maintains DexCom (NASDAQ:DXCM) with a Buy and lowers the price target from $145 to $132.

Stifel分析师马修·布莱克曼维持德康医疗(纳斯达克股票代码:DXCM)的买入评级并将价格目标从145美元下调至132美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发